Dyne Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Let's go. Okay, great. Good afternoon, everyone. My name is Jason Russell with the Morgan Stanley banking team, pleased to be joined here by Josh Brumm, President and CEO; and Wildon Farwell, Chief Medical Officer of Dyne.
Before I jump in, just to read you the disclosure, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Great. So we're very honored to have the Dyne team join us again this year at the conference. As you may know, Dyne has a very exciting series of upcoming events, and I think we'll jump into that. Probably most important will be the company's two readouts, DYNE-101 and DM1 patients from the ACHIEVE study expected the second half of this year, as well as DYNE-251 in DMD. So I think we'll spend a little bit of time on both of those.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
